CDCA7L Polyclonal Antibody
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-5963R |
| Product Name | CDCA7L Polyclonal Antibody |
| Applications |
ELISA
IHC-P
IHC-F
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human, Mouse, Rat |
| Predicted Reactivity | Dog, Cow, Pig, Horse, Chicken, Rabbit |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human CDCA7L |
| Immunogen Range | 381-454/454 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target | |
| Gene ID | 55536 |
| Subcellular location | Cytoplasm, Nucleus |
| Synonyms | c Myc Interacting protein JPO2; DKFZp762L0311; RAM2; HR1; JPO2; Protein JPO2; R1 antibody Transcription Factor RAM2.CDA7L_HUMAN |
| Background | CDCA7L is a member of the CDCA (cell division cycle associated) protein family. Members of this family have expression patterns associated with other known cell cycle genes such as cyclins and CDC genes. CDCA7L plays a role in transcriptional regulation as a repressor that inhibits monoamine oxidase A (MAOA) activity and gene expression by binding to the promoter. It also plays an important oncogenic role in mediating the full transforming effect of MYC in medulloblastoma cells. It is involved in apoptotic signaling pathways and may act downstream of P38-kinase and BCL-2, but upstream of CASP3/caspase-3 as well as CCND1/cyclin D1 and E2F1. |
| Application Dilution | |
| ELISA | 1:500-1000 |
| IHC-P | 1:200-400 |
| IHC-F | 1:100-500 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |